ImmuCell (NASDAQ:ICCC) Stock Passes Above 200 Day Moving Average – Time to Sell?

ImmuCell Co. (NASDAQ:ICCC)’s stock price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.44 and traded as high as $4.93. ImmuCell shares last traded at $4.85, with a volume of 12,836 shares changing hands.

ImmuCell Stock Performance

The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 3.11. The stock has a 50 day moving average of $5.14 and a 200 day moving average of $4.44. The stock has a market capitalization of $43.22 million, a P/E ratio of -9.70 and a beta of 0.62.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings results on Tuesday, February 25th. The biotechnology company reported $0.06 EPS for the quarter. The business had revenue of $7.75 million during the quarter. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%.

Institutional Investors Weigh In On ImmuCell

A number of hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new stake in ImmuCell in the 4th quarter valued at approximately $149,000. Northern Trust Corp boosted its position in ImmuCell by 51.0% during the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock worth $229,000 after acquiring an additional 14,982 shares during the period. Dauntless Investment Group LLC bought a new position in shares of ImmuCell in the fourth quarter worth $676,000. Geode Capital Management LLC increased its holdings in shares of ImmuCell by 13.9% during the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock valued at $332,000 after purchasing an additional 7,878 shares during the period. Finally, Mesirow Financial Investment Management Inc. raised its stake in shares of ImmuCell by 100.0% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 12,178 shares in the last quarter. Institutional investors own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.